Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track designation from the US Food and Drug Administration (FDA) for its Phase II study of OVV-01. This recombinant vesicular stomatitis virus (VSV) carrying the NY-ESO-1 tumor-associated antigen is being investigated for the treatment of advanced soft tissue sarcomas.
Mechanism of Action
OVV-01 is designed to specifically replicate within and lyse tumor cells, releasing various tumor antigens and expressing the strong immunogenic NY-ESO-1 antigen. By regulating the tumor immune microenvironment, OVV-01 induces tumor-specific immune responses, promoting T cell activation, expansion, and recruitment of infiltrating T cells while modulating immune suppression within the tumor to enhance antitumor activity.-Fineline Info & Tech
Leave a Reply